Lataa...
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment
Sorafenib (SOR) is a multi-kinase inhibitor that was approved as the first-line systematic treatment agent of hepatocellular carcinoma (HCC). However, the anti-cancerous effect of SOR is dramatically impaired by the drug resistance, insufficient accumulation at tumor tissues, and limited tumor inner...
Tallennettuna:
| Julkaisussa: | Drug Deliv |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6882497/ https://ncbi.nlm.nih.gov/pubmed/31735093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2019.1654040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|